$0.59
4.42% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US75955J2042
Symbol
RLMD

Relmada Therapeutics Inc Stock price

$0.59
-0.04 6.29% 1M
+0.28 92.85% 6M
+0.07 13.08% YTD
-1.71 74.43% 1Y
-28.51 97.98% 3Y
-36.67 98.42% 5Y
-26.41 97.82% 10Y
-59.41 99.02% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.02 4.42%
ISIN
US75955J2042
Symbol
RLMD
Industry

Key metrics

Basic
Market capitalization
$18.7m
Enterprise Value
$-8.4m
Net debt
positive
Cash
$27.1m
Shares outstanding
33.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.8
Financial Health
Equity Ratio
77.5%
Return on Equity
-225.2%
ROCE
-352.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-105.6m
EBIT
$-79.1m | $-61.8m
Net Income
$-75.7m | $-65.3m
Free Cash Flow
$-56.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
19.7% | 26.3%
Net Income
19.7% | 18.3%
Free Cash Flow
-17.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.5
FCF per Share
$-1.7
Short interest
1.3%
Employees
17
Rev per Employee
$0.0
Show more

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

Hold
57%
Sell
43%

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
26% 26%
-
- Research and Development Expense 45 45
14% 14%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -79 -79
20% 20%
-
Net Profit -76 -76
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
Seeking Alpha
4 days ago
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Maged S. Shenouda - Chief Financial Officer Raj S.
Neutral
GlobeNewsWire
5 days ago
6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndro...
Neutral
GlobeNewsWire
13 days ago
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second qua...
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Sergio Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today